Adma Biologics reported $408.21M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 408.21M 17.88M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Novavax USD -190.71M 45.94M Jun/2026
Omeros USD -228.68M 15.13M Jun/2025
Takeda JPY 7.56T 215.7B Jun/2026